INTRODUCTION
Human influenza A viruses (IAVs) are major causative agents of respiratory tract infections and cause excess morbidity and mortality every year. Occasionally, novel IAVs are introduced into the human population that have pandemic potential, as protective antibodies to these viruses are virtually absent in the population. Subsequently, these viruses perpetuate in humans, facilitated by antigenic drift allowing them to escape recognition by virus-neutralizing antibodies induced by previous infections.
Birds form the reservoir for most IAV subtypes, and direct transmission of avian IAVs of the H9N2, H7N7 and H5N1 subtypes to humans has been described (Fouchier et al., 2004; Lin et al., 2000; Ungchusak et al., 2005; WHO, 2010; Yang et al., 2007) . Highly pathogenic avian IAVs of the H5N1 subtype are of particular concern, as these viruses can cause severe disease and have the potential to become transmissible via aerosols or respiratory droplets, as was demonstrated recently in ferret models (Herfst et al., 2012; Imai et al., 2012) .
In addition, IAVs are transmitted regularly from pigs to humans (Claas et al., 1994; de Jong et al., 1997 de Jong et al., , 1986 Gaydos et al., 1977; Patriarca et al., 1984; Rimmelzwaan et al., 2001; Wentworth et al., 1994) and may cause severe disease.
As epithelial cells of the pig respiratory tract possess receptors for both human and avian IAVsa-2,6-and a-2,3-linked sialosaccharides, respectively (Matrosovich et al., 1997; Rogers & D'Souza, 1989; Suzuki, 2005; Thompson et al., 2006 ) -these animals can be infected with both viruses, which allows reassortment of gene segments to take place and reassortant viruses to emerge (Ito et al., 1998) . In this way, novel IAVs may acquire the property to replicate in humans efficiently and become transmissible from human to human, which may result in a pandemic outbreak. It is generally believed that the A (H2N2) and A (H3N2) viruses that caused the pandemics in 1957 and 1968, respectively, originated this way.
In 2009, influenza A (H1N1) viruses of swine origin [A(H1N1)pdm09 virus] caused the first pandemic of the 21st century, which was first noted in Mexico in March 2009 (Girard et al., 2010; Neumann et al., 2009) . This virus possessed a genome consisting of gene segments of various IAVs. Its haemagglutinin gene was derived from classical swine H1N1 viruses (Garten et al., 2009) . The virus rapidly spread worldwide and caused disease, especially in children and young adults (Dawood et al., 2012; WHO, 2009) . Recently, swine A (H3N2) IAVs have emerged in the USA that, by reassortment, have acquired the gene segment encoding the matrix (M) proteins of the A(H1N1)pdm09 virus. These viruses are called swine-origin triple-reassortant A (H3N2) viruses [A(H3N2)v] (WHO, 2011) and have caused several human infections, including in children (CDC, 2011a (CDC, , 2012a Olsen et al., 2006; Yang et al., 2004) . Furthermore, these viruses are transmissible from human to human (CDC, 2011b (CDC, , 2012c and have been shown to be transmissible in ferrets and pigs (Ducatez et al., 2011; Fan et al., 2012; Pearce et al., 2012) .
As the A(H1N1)pdm09 virus was not of a novel subtype, it was expected that pre-existing antibodies to seasonal A (H1N1) (sH1N1) viruses would cross-react with the pandemic strain and afford some protection. Indeed, elderly people who had been exposed to sH1N1 viruses that circulated in the 1950s and that resembled the pandemic strain antigenically had cross-reacting antibodies that afforded some protection against the pandemic strain in this age group (Hancock et al., 2009) . There also seems to be an age-dependent seroprevalence of antibodies against A(H3N2)v viruses (Skowronski et al., 2012a) . A proportion of adults aged 20-59 years have protective antibody levels against A(H3N2)v virus, but these antibodies are virtually absent in children of ,10 years of age.
As IAV-specific T-cells induced by previous infections are predominantly directed to more conserved proteins like the nucleoprotein (NP) and the M protein, they can crossrecognize IAVs of other subtypes and contribute to so-called heterosubtypic immunity (Grebe et al., 2008; Hillaire et al., 2011a) . Indeed, T-cells induced by infection with seasonal A (H3N2) (sH3N2) virus afforded protection against infection with A(H1N1)pdm09 virus in mice (Hillaire et al., 2011b) . In particular, CD8 + cytotoxic T-lymphocytes (CTLs) are believed to play an important role in heterosubtypic immunity. However, the extent of cross-reactivity of human virus-specific CD8 + T-cells with A(H1N1)pdm09 and A(H3N2)v viruses is largely unknown.
In the present study, we assessed the cross-reactivity of human CD8 + T-lymphocytes induced by infection with sH1N1 or sH3N2 IAVs with A(H1N1)pdm09 and A(H3N2)v viruses. Although some T-cell clones failed to recognize peptide variants derived from the swine-origin IAVs, the polyclonal CD8 + T-cell response was highly crossreactive with both viruses, and it is anticipated that T-cells induced after infection with seasonal IAVs will contribute to protection against the swine-origin influenza viruses.
RESULTS

Comparison of amino acid sequences of CD8 + T-cell epitopes
To analyse the amino acid sequence of CD8 + T-cells epitopes present in A(H1N1)pdm09 and A(H3N2)v viruses, these sequences were compared with those of sH3N2 IAV. To this end, epitopes matching the HLA alleles of the subjects used in the present study (Table 1) were derived from the Influenza Virus Resource database (http://www. ncbi.nlm.nih.gov/genomes/FLU/Database/nph-select.cgi?go= database). In total, 1894 sequences of the non-structural NS1 protein were analysed and 1892 sequences of the NP of A(H1N1)pdm09 viruses. As shown in Table 2 , two major variants of the NS1 122-130 epitope were identified (AVMEKNIVL and AIMEKNIVL) that differed from the sequence in sH3N2 viruses. Minor variant were not included into this study, as it has been demonstrated previously that they show little or no cross-reactivity (Kreijtz et al., 2008) . Most of the A(H1N1)pdm09 viruses contained epitopes of NP [44] [45] [46] [47] [48] [49] [50] [51] identical to those observed in sH3N2 viruses. However, some minor variants were observed with a relatively low prevalence, which were tested for recognition by virus-specific T-cells. The A(H1N1)pdm09 variant of the NP 418-426 epitope was not analysed further, as this has been done extensively in a recent study (Gras et al., 2010) .
The amino acid sequences of the epitopes of A(H3N2)v virus A/Indiana/08/11 were identical to those of sH3N2 viruses with the exception of NS1 122-130 and NP [418] [419] [420] [421] [422] [423] [424] [425] [426] (AIMEKNIIL and LPFERATVL, respectively).
Recognition of A(H1N1)pdm09 and A(H3N2)v epitopes by CD8 + T-cell clones
CD8 + T-cell clones specific for epitopes present in sH3N2 viruses were tested for their ability to recognize A(H1N1)pdm09 and A(H3N2)v variants of these epitopes using a gamma interferon (IFN-c) ELIspot assay. MHC class I-matched B-lymphoblastoid cell line (BLCL) cells were loaded with the respective peptides and used for stimulation of the corresponding CD8 + T-cell clones. NS1 122-130 (AIMDKNIIL)-specific T-cells displayed poor cross-reactivity with the two major variants of A(H1N1)pdm09 viruses (Fig. 1 ). The clone directed to the NP 184-194 epitope (RRSGAAGAAVK) responded poorly to the variants RKSGAAGAAVK and RRSGAAGAAVE, but responded well to stimulation with the minor variant RRSGAAGAAMK. The clones specific for NP [380] [381] [382] [383] [384] [385] [386] [387] [388] and NP 44-51 all responded well after stimulation with the respective A(H1N1)pdm09 peptide variants.
The T-cell clone specific for the NP 418-426 epitope (LPFEKSTVM) did not recognize its counterpart (LPFERATVL) derived from A(H3N2)v virus A/Indiana/ 08/11 ( Fig. 1 ).
Recognition of A(H1N1)pdm09 and A(H3N2)v epitope variants by polyclonal virus-specific CD8 + T-cell preparations
Next, we wished to assess whether pre-existing CD8 + Tcells directed to sH3N2 and sH1N1 viruses that circulated before 2009 cross-reacted with A(H1N1)pdm09 and A(H3N2)v viruses. To this end, PBMCs isolated before 2009 from healthy blood donors of three different MHC class I haplotypes ( Fig. 2 and Table 1 ) were stimulated with sH1N1 or sH3N2 virus and the in vitro-expanded virusspecific CD8 + T-cells were tested for reactivity with the epitope variants listed in Table 1 .
After stimulation with sH3N2 virus, in vitro-expanded Tcells of group I subjects (HLA-A*0101, -A*0201, -B*0801, -B*3501) displayed poor reactivity against the NP 44-51 and NP 380-388 epitopes and their variants ( Fig. 2a ). Only donor 1 had T-cells responding to the NS1 122-130 epitope, and these T-cells cross-reacted with the A(H1N1)pdm09 variant AVMEKNIVL. After stimulation with sH1N1 virus, low reactivity was observed with the NP 380-388 epitope and its variant ( Fig. 2b) and also with the NP 44-51 epitope, although some reactivity was observed with the rare A(H1N1)pdm09 variant CTELKLNDY. Three of the four donors tested had T-cells that responded to the NS1 122-130 epitope but that failed to recognize the variant epitopes. In contrast, donor 1 did not have T-cells recognizing this epitope but displayed reactivity with the two variant epitopes AIMEKNIVL and AVMEKNIVL.
T-cell cultures obtained after sH3N2 stimulation of PBMCs from group II (HLA-A*0101, -A*0201, -B*0801, -B*3501) responded to the NP 184-194 epitope and displayed crossreactivity with the A(H1N1)pdm09 variants RRSGAA-GAAVE and RRSGAAGAAMK but not RKSGAAGAAV-K (Fig. 2c ). These two peptides were also recognized preferentially by sH1N1-stimulated T-cell cultures of donors 6 and 7 ( Fig. 2d ). After stimulation with sH3N2 virus, T-cell cultures of most donors responded to the NS1 122-130 and the NP 380-388 epitope and their A(H1N1)pdm09 variants. The response to these epitopes after stimulation with sH1N1 virus was relatively low and cross-reactivity was barely observed. The T-cell culture did not respond to the NP 44-51 epitope, although some low-level reactivity was observed with the variant CTELKLNDY for some donors.
A similar pattern of recognition of the NP 44-51 epitope was observed with T-cell cultures obtained from subjects of Table 2 . IAV CD8 + T-cell epitopes analysed in this study
The sequences of A(H1N1)pdm09 (pH1N1) and A(H3N2)v were downloaded from the Influenza Virus Resource database. The percentage of viruses with the respective variants of the epitopes is given. Fig. 2 . Polyclonal CD8 + T-cell populations recognize A(H1N1)pdm09 and A(H3N2)v epitope variants to variable extents. CD8 + T-cells isolated from PBMCs that had been stimulated in vitro with sH3N2 (a, c, e) or sH1N1 (b, d, f) were incubated with BLCL cells that had been pulsed with peptide variants of A(H3N2)v and A(H1N1)pdm09 viruses. Three groups of donors with identical HLA A and B alleles were used. Secretion of IFN-c was detected by ELIspot assay. Experiments were performed in duplicate. group III (HLA-A*0101, -A*0301, -B*0801, -B*3501). After stimulation with sH1N1 and sH3N2 viruses, T-cells responded to the NP 380-388 epitope and its variant ( Fig.  2e, f ). Almost all subjects tested responded to the NP 265-273 epitope, with some cross-reactivity with A(H1N1)pdm09 variant VLRGSVAHK. T-cells of two donors (9 and 11) responded to the LPFEKSTVM epitope (NP 418-426 ) after sH3N2 stimulation, with little cross-reactivity with the A(H1N1)pdm09 variant. After stimulation with sH1N1, Tcell cultures virtually did not respond to the NP 418-426 epitope (LPFEKSTVM, derived from viruses of the H3N2 subtype) or the A(H1N1)pdm09 variant of this epitope.
Recognition of BLCL cells infected with A(H1N1)pdm09 and A(H3N2)v virus by virusspecific CD8 + T-cells
Next, we assessed the cross-reactivity of the polyclonal Tcell populations raised against sH1N1 and sH3N2 viruses with A(H1N1)pdm09 or A(H3N2)v virus. To this end, MHC class I-matched BLCL cells were infected with sH1N1, sH3N2 or A(H1N1)pdm09 virus and incubated with the in vitro-expanded CD8 + T-cells from the donors. The number of IFN-c-producing cells per 10 4 cells was determined after stimulation with the virus, and the relative number of spots compared with the number detected with the virus used for expansion of the T-cells was calculated for each donor. Thus, a ratio close to 1 was indicative of high cross-reactivity, comparable to homologous recognition. In Fig. 3(a, b) , the mean ratios of crossreactivity are shown. sH3N2-and sH1N1-stimulated CD8 + T-cells responded to BLCL cells infected with A(H1N1)pdm09 virus (mean ratios of 0.87±0.6 and 0.73±0.5, respectively).
Four high-responding donors (1, 4, 6 and 10) were also tested with MHC class I-matched BLCL cells infected with A(H3N2)v virus. CD8 + T-cells specific for sH3N2 and sH1N1 viruses efficiently recognized BLCL cells infected with A(H3N2)v virus, in addition to those infected with the heterologous subtype of seasonal virus or A(H1N1)pdm09 (Fig. 3c, d ).
Next, we assessed the lytic activity of the virus-specific CD8 + T-cell populations as an alternative functional readout for CD8 + T-cell activation (Fig. 4) . CFSE-labelled BLCL cells infected with sH3N2, sH1N1, A(H1N1)pdm09 or A(H3N2)v virus were used as target cells and incubated with CD8 + T-cells obtained from sH1N1-or sH3N2-stimulated PBMCs from donors 4, 6 and 10. As shown in Fig. 4 , BLCL cells infected with A(H1N1)pdm09 or A(H3N2)v virus were lysed by sH3N2-and sH1N1-specific CD8 + T-cells from donor 10 (group III) to various extents. In contrast, CD8 + T-cells from donor 6 (group II) displayed lytic activity against the homologous virus used for stimulation of the PBMCs, with little or no activity against heterologous viruses including A(H1N1)pdm09 and A(H3N2)v viruses. CD8 + T-cells obtained after stimulation of PBMCs of donor 4 (group I) with sH3N2 virus did not display any lytic activity, even against the homologous virus. However, sH1N1-specific CD8 + T-cells of this donor lysed BLCL cells infected with the homologous virus and those infected with A(H3N2)v virus.
Recognition of A(H3N2)v virus by A(H1N1)pdm09specific CD8 + T-cells
PBMCs were obtained in 2011 from two donors (13 and 14) that had probably been exposed to A(H1N1)pdm09 virus as they displayed virus-neutralizing antibodies against A(H1N1)pdm09. Subsequently, these PBMCs were stimulated with A(H1N1)pdm09 virus and the expanded CD8 + T-cells were tested for their capacity to recognize A(H3N2)v virus by ELIspot and CTL assay. Table 3 , BLCL cells infected with A(H3N2)v virus were lysed by A(H1N1)pdm09-specific CD8 + T-cells. These results were confirmed by the results obtained in the ELIspot assay, where A(H1N1)pdm09-specific CD8 + Tcells secreted IFN-c in response to incubation with A(H3N2)v-infected BLCL cells.
As shown in
DISCUSSION
In the present study, we demonstrated that influenza virusspecific CD8 + T-cells induced after infection with seasonal IAVs can cross-react with A(H1N1)pdm09 and A(H3N2)v viruses. It is likely that this pre-existing cell-mediated immunity contributed to protection against A(H1N1)pdm09 viruses during the 2009 pandemic and could afford individuals protection against A(H3N2)v virus infections.
Most of the CD8 + T-cell clones specific for individual epitopes were able to recognize BLCL cells pulsed with variant peptides derived from the amino acid sequence of A(H1N1)pdm09 viruses. Most of these epitopes were identical in A(H3N2)v viruses. Furthermore, most CD8 + T-cells obtained from T-cell cultures stimulated in vitro with sH1N1 or sH3N2 virus displayed cross-reactivity against the NP [44] [45] [46] [47] [48] [49] [50] [51] and NP 380-388 epitope variants of A(H1N1)pdm09 viruses. For most of these epitopes, the majority of A(H1N1)pdm09 viruses shared identical epitope sequences with the seasonal IAVs. The conservation of epitope sequences probably contributed to the induction of cross-reactive CD8 + T-cells.
CD8 + T-cells directed to epitopes NP [418] [419] [420] [421] [422] [423] [424] [425] [426] displayed little cross-reactivity, and the subjects responded to variable extents to these epitopes. However, for most of the blood donors, the polyclonal T-cell populations directed to seasonal IAVs recognized BLCL cells infected with A(H1N1)pdm09 or A(H3N2)v virus efficiently, confirming that the cross-reactivity of human CD8 + T-cell responses to sH1N1 or sH3N2 viruses with A(H1N1)pdm09 or A(H3N2)v viruses is substantial. Our findings are in agreement with those of others (Gras et al., 2010; Tu et al., 2010) . Upon stimulation with these novel viruses, the CD8 + T-cells IP: 54.70.40.11
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PBMCs obtained from two donors after the pandemic of 2009 were stimulated in vitro with A(H1N1)pdm09 virus and subsequently tested for cross-reactivity with A(H3N2)v virus. These two subjects had probably experienced an infection with the pandemic H1N1 strain, as demonstrated by the presence of serum antibodies to this virus in a virusneutralization assay. The A(H1N1)pdm09-specific CD8 + T-cells were highly cross-reactive with A(H3N2)v virus, which may be explained by the high sequence homology of the internal structural proteins, in particular the M protein (CDC, 2011b).
Although the 2009 H1N1 pandemic was considered mild, the death toll was probably much higher than that based on reported cases (Dawood et al., 2012) . During the pandemic, the incidence of severe cases displayed a disproportionate age distribution. Elderly people were less likely to develop the disease than children and young adults (Hancock et al., 2009) , which correlated with the presence of antibodies that cross-reacted with A(H1N1)pdm09 virus and were induced originally after infection with sH1N1 viruses that circulated before 1957. Thus, the highest burden of disease caused by A(H1N1)pdm09 virus was observed in children. A similar observation has been made for cases of infections with A(H3N2)v virus. The majority of these cases concern children ,10 years of age. Children lack virus-specific antibodies to these variant H3N2 viruses, but these antibodies have been detected in subjects of older age (Skowronski et al., 2012a) . In addition, early in life, children may not have been infected at all with seasonal IAVs (Bodewes et al., 2011) and thus may not have developed virus-specific T-cells. The absence of (cross-reactive) cell-mediated immunity may further increase the susceptibility to infection with novel antigenically distinct IAVs in this age group (Bodewes et al., 2011) . Furthermore, a recent serological study showed that only 25 % of the population have cross-reactive antibodies against A(H3N2)v viruses, and vaccination with currently used trivalent inactivated vaccines did not improve seroprotection (Skowronski et al., 2012b) . This highlights the importance of the induction of a strong T-cell immunity to protect the population against A(H3N2)v virus infection. Of interest, T-cells specific for sH3N2 and sH1N1 viruses also recognize and cross-react with IAVs of the H5N1 subtype (Jameson et al., 1999; Kreijtz et al., 2008; Lee et al., 2008) .
In conclusion, the extent of cross-reactivity of CD8 + Tcells is substantial and expands to recent IAVs of swine origin that have the capacity to infect and spread among humans. Pre-existing T-cell immunity may have contributed to mitigating the impact of the 2009 H1N1 pandemic. As both CD4 + and CD8 + T-cells contribute to protective immunity (Hillaire et al., 2011b; Lukacher et al., 1984; McMichael et al., 1983; Seo & Webster, 2001; Taylor & Askonas, 1986; Wilkinson et al., 2012; Yap et al., 1978) , the development of vaccines that aim to induce virus-specific (Rimmelzwaan et al., 1998) .
In vitro expansion of IAV-specific CD8 + T-cells. PBMCs were obtained from 12 healthy blood donors between 1999 and 2008 and from two donors in 2011. The cells were isolated by density-gradient centrifugation using Lymphoprep (Nycomed) and cryo-preserved at 2135 uC. The donors selected for this study were between 35 and 50 years of age, thereby controlling for age-related differences in immune reactivity and reducing the impact of the number of times the donors had been infected with influenza virus. All study donors had serum antibodies to the viral NP, indicating that they had been infected with one or more IAV in the past. Although the vaccination status was not known, it is unlikely that any of the study subjects was vaccinated. All were healthy blood donors of 35-50 years of age and for these subjects influenza vaccination is not recommended in The Netherlands. Three groups of donors were selected according to serological homology within the A and B loci of HLA class I molecules, as described previously (Boon et al., 2004a) . The different groups are shown in Table 1 .
PBMCs were stimulated with sH1N1, aH3N2 or A(H1N1)pdm09 virus at an m.o.i. of 2 TCID 50 , essentially as described previously (Boon et al., 2002) . Eight days after stimulation, the cells were harvested and the CD8 + T-cells purified from the in vitro-stimulated PBMCs by CD8 MACS bead sorting (Miltenyi Biotec). These cells were used as effector cells in an ELIspot or a CTL assay (see below), Permission to use the PBMCs for scientific research was obtained from the blood donors by informed consent.
Virus-specific CD8 + T-cell clones. CD8 + T-cell clones specific for the HLA-A*0101-restricted NP 44-52 epitope (CTELKLSDY), HLA-A*0201-restricted NS1 122-130 epitope (AIMDKNIIL), HLA-A*0301 restricted NP 265-273 epitope (ILRGSVAHK), HLA-B*0801-restricted NP 380-388 epitope (ELRSRYWAI), HLA-B*2705-restricted NP [184] [185] [186] [187] [188] [189] [190] [191] [192] [193] [194] epitope (RRSGAAGAAVK) and HLA-B*3501-restricted NP 418-426 epitope (LPFEKSTVM) were generated as described previously (Boon et al., 2004b; Voeten et al., 2000) .
Epitope selection. Amino acid sequences of known human IAV CD8 + T-cell epitopes that matched the HLA alleles of the study subjects were compared with those present in A(H1N1)pdm09 viruses circulating between March 2009 and June 2010, and A(H3N2)v virus A/Indiana/08/ 2011. Sequences of A(H1N1)pdm09 viruses were downloaded from the Influenza Virus Resource database (http://www.ncbi.nlm.nih.gov/ genomes/FLU/Database/nph-select.cgi?go=database). MAFFT multiple alignment software (http://www.ebi.ac.uk/Tools/msa/mafft/) was used to perform the alignment of NS1 and NP proteins. The alignments were then used to check epitope conservation, as described previously (Bui et al., 2007) . The list of epitopes that were analysed is shown in Table 2 .
ELIspot assay. Epstein-Barr virus-transformed BLCL cells were incubated overnight with 100 mM peptides or infected with sH3N2 virus or sH1N1 virus at an m.o.i. of 2 and used as stimulator cells in an ELIspot assay. As effector cells, cells of virus-specific CD8 + T-cell clones or in vitro-expanded polyclonal CD8 + T-cell populations were used. For use with the T-cell clones, 3000, 1000, 300 and 0 effector cells were incubated with 30 000 stimulator cells per well for 5 h, essentially as described previously (Boon et al., 2002 (Boon et al., , 2004b . In the case of in vitro-expanded CD8 + T-cells, 10 000 effector cells were used. In brief, 96-well plates were coated with 2.5 mg anti-IFN-c mAb 1-D1K (Mabtech) ml 21 and blocked with RPMI containing 10 % human AB serum (Sanquin Blood Bank, Rotterdam, The Netherlands), antibiotics and 20 mM b-mercaptoethanol (R10H). After incubation of effector cells with stimulator cells, IFN-c production was detected using an enzyme-labelled mAb to IFN-c (Mabtech) . The number of spots was counted using an automated ELIspot reader (Aelvis; Sanquin Blood Bank). Experiments were performed in duplicate.
CTL assay. MHC class I-matched BLCL cells were incubated with 50 mM CFSE for 5 min and infected with sH1N1, sH3N2, A(H1N1)pdm09 or A(H3N2)v virus at an m.o.i. of 2. After incubation at 37 uC for 16 h, infected CSFE-labelled BLCL cells were used as target cells and in vitro-expanded CD8 + T-cells as effector cells. Various effector : target (E : T) ratios were used (5, 2.5 and 1.25). After 3 h incubation, the percentage lysis was determined by flow cytometry using BD FACSDiva software. Experiments were performed in triplicate.
